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Debilitated by years of economic instability, the Spanish economy has not fully 
rebounded to its once strong place in the European market. And now, in the aftermath 
of a devastating pandemic, the nation will be searching for new sources of wealth. The 
lucrative market potential of controlled cannabis in medicinal and recreational settings 
is an attractive industry gaining popularity across Europe. This paper explores the 
various policy models and legal systems in Portugal, Germany, and the Netherlands. 
Combining a variety of sources, I seek to ascertain the best plan for Spain. Ultimately, 
analysis shows that a multi-pronged approach is the most shrewd way to introduce more 
progressive policy to Spain. This policy would include a fully integrated domestic 
cannabis industry, a cultural, non-partisan shift away from stigma, and market 









Humans have walked this earth in organized communities for two million years. 
Knowledge of cannabis cultivation dates back 12,000 years in China, where 
archeological records indicate that early human societies grew it as a remedy for aches 
and pains.  The plant originally evolved in Asia before being traded over into 
1
modern-day Europe, Africa, and finally, the Americas. 
 
Most plant-based drugs can only be grown in a few specialized climates. “Weed” has 
earned its nickname for its resiliency, and can be found growing in just about every 
country in the world. If you closed your eyes, spun a globe, and pointed your finger at 
random, chances are that the drug policy in the country you landed on is unique from its 
neighbor. After thousands of years, humans still have not come to a consensus on the 
appropriate use and regulation of these reality-altering substances. Perhaps we can 
attribute our global political dissonance to just that: ​Cannabis sativa ​has the power to 
erase pain, cure ailments, decrease stress, improve our quality of life, and change our 
minds. Things that a complex, national governmental system promises to do can be 
achieved by a plant. It’s powerful.  
 
Government treatment of the ​Cannabis sativa​ plant is a long and complex history 
including many twists and turns that sometimes evade scientific fact. One constant that 
has held true through time is cannabis’s tether to social norms. In studying this 
substance, one cannot ignore the strong correlation between its success with social 
acceptance. 
 
What complicates the academic study of cannabis regulation is that there is no 
one-size-fits-all regulation structure. The reason for this is that in every country, 
cannabis is rooted in a different social, cultural, and economic framework. However, the 
multitude of policy structures around the world offers an opportunity for analysis. 
International policy organizations can learn from this diversity of cases to draw 
blueprints for the appropriate management of cannabis in a particular country.  
 
About 188 million people around the world are cannabis users.  In Europe, 26.3 percent 
2
of adults have ingested cannabis at some point in their lives. These numbers have seen a 
net increase over the last 20 years. Over the past 20 years, Europe has been washed over 
with a tidal wave of progressive cannabis policy. In 2017 alone, five countries legalized 
1 From “Cannabis: Evolution and Ethnobotany,” by R. Clarke and M. Marlin, 2013,  pp. 13 - 28, 
www.jstor.org/stable/10.1525/j.ctt3fh2f8.9 
2 From “World Drug Report,” by the United Nations Office on Drugs and Crime, 2019, p. 17. 
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medical cannabis. This moment in time is a watershed for the cannabis industry. 
Industry analysts have dubbed the excitement swirling around the potential of cannabis 
“The Green Rush” to draw connections to the California Gold Rush. While “weed” is 
gaining acceptance worldwide as an essential good, it seems appropriate to investigate 
the policy models undergirding cannabis.  
 
As a commodity, cannabis has endured 
punishing policies for decades. This 
survival is a testament to its undeniable 
impact on humans recreationally and 
medicinally. It seems that we cannot live 
with it or without it.  
 
Botany & Biology 
The plant ​Cannabis sativa​ has one of the 
worst and longest-running P.R. campaigns. 
We know it by many other nicknames and 
slang words, so let’s define it here. 
Cannabis is a prolific plant that grows in a 
variety of climates, and can be genetically 
bred into many different strains. The two 
main varieties are known as marijuana and 
hemp. 
 
The ​Cannabis Sativa ​plant is a deep 
vibrant green, with palmate leaves that fan into seven-lobed fingers with pronounced 
serrated edges. Depending on the genetic origin of the plant, the leaves can be arranged 
in opposite, alternate, or spiral placement on the stem. These leaves, achieving 2 - 5 
inches in length, shoot off from a stiff central stem (​cannabis ​translates to “cane-like”), 
which transports carbon, nitrogen, minerals and other nutrients between soil and plant. 
The stem can soar to twenty feet in height, and burrow roots down into the soil up to 
approximately eight feet deep.   
3
 
Cola refers to bunches of flowers growing closely together on several locations along the 
stem. ​Cannabis sativa​ reproduces through stigma, bract/calyx, Trichomes are 
structures that dot the top of the plant, or the female flower. These tiny filaments 
3 From “Handbook on Cannabis and Related Pathologies,” S. Farag and O. Kayser, 2017, pp. 3-12, 
Technical University Dortmund, ​https://doi.org/10.1016/B978-0-12-800756-3.00001-6 
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manufacture the strong compounds that cannabis is known for: terpenes, cannabinoids, 
and flavonoids. 
 
Marijuana vs. Hemp 
The two strains of cannabis appear to be identical phenotypically and are genetically 
similar. Marijuana contains high levels of THC, a psychoactive chemical that stimulates 
a depressant response in the body. Hemp is marijuana’s twin sister. It contains very low 
levels of THC, and high levels of CBD. CBD, or cannabidiol, is a natural compound that 
can be extracted as an oil and infused into tinctures, balms, foods — just about anything. 
Both hemp and marijuana can be processed and used both medicinally and 
recreationally. In order to be consumed, the flower (or “bud”) must first be harvested, 
dried, and cured. For use in informal settings, the processed product is typically ground 
up, burned, and the psychoactive ingredients are inhaled as smoke. However, there are 
many alternative ways that people choose to ingest the herb or resin to get the desired 
mind-altering effect.   
4
 
Scientists understand that CBD reduces bodily inflammation by acting on the 
endocannabinoid system. To date, the European Medicines Agency has approved few 
CBD medications. One of them, Epidiolex, is the only FDA approved CBD drug in the 
United States, and is prescribed to treat epileptic patients. However, the CBD market is 
bursting with products boasting health claims ranging from calming menstrual cramps 
to reducing cancer risk. The EMA has clearly indicated their curiosity in 
cannabinoid-based medicines and has assigned orphan designation — usage to treat a 
rare disease or condition upon request of a sponsor — for many medicines  over the past 
few years.   
5
 
The CBD industry is still in its ​bildungsroman​ (as they say in Germany) in Europe, 
however, according to population surveys, the substance is already gaining popularity 
among consumers. In one poll by New Frontier Data,​ ​more than 50 percent of 
consumers responded that CBD has improved their quality of life. Seventy-two percent 
of consumers and 17 percent of nonconsumers said that they were likely to buy a CBD 
product in the next six months.  Although medical research is still preliminary, there is 
6
promising evidence that this substance can be very beneficial.  
4 From “Defining Hemp: A Fact Sheet,” Congressional Research Service, 2019, crsreports.congress.gov 
5 From “Designating an Orphan Drug or Biologic,” U.S. Food and Drug Administration, 2020, 
www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-an
d-biological-products. 
6 From “The EU CBD Consumer Report Series: Segmentation and Archetypes,” New Frontier Data, 2020, 
https://newfrontierdata.com/eucbdpt2 
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According to industry analysis reports from 2019, all the active cannabis markets in 
Europe sum to 240 million euros. This number accounts for sales of every derivative of 




This paper will determine what obstacles and circumstances have obstructed the 
realization of this potentiality. A desired result of this paper is to determine 
standardized criteria to assess “cannabusiness” infrastructure readiness within Spain. 
Policymakers in Spain can learn from the successes and failures of cannabis regulation 
models in other European countries to apply to their own market. In doing so, the 
nation can avoid being left behind in this lucrative, fast-growing market.  
 
Literature Review 
Much has changed since 2001 — many more European countries and U.S. states have 
legalized or decriminalized — but Robert MacCoun and Peter Reuter’s study of “legal 
regimes” to control cannabis published that year provides key insights. In reviewing the 
existing models in the U.S., Australia, and the Netherlands, the authors found that  “A 
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model of depenalised possession and personal cultivation has many of the advantages of 
outright legalisation with few of its risks.”  8
 
Disclaimer: This paper centers on a highly controversial substance. Even presenting it in 
a positive light connotes political bias. I acknowledge that this paper cannot achieve a 
conclusive, multi-faceted view of the cannabis policy debate. One example is how the 
legality of this substance is disproportionately enforced. Under alternate research 
circumstances, I would have included interviews with people of varying identities to 





Removing all punishable offenses from the consumption, cultivation, sale, prescription, 
and other manner of distribution of a substance. Legalization does not mean 
unregulated free use, and partial legalization of a substance is not uncommon. 
Marijuana legalization activists promote that enacting this kind of policy reduces harm 
on those charged (sometimes disproportionately across a population) and prevents gang 
violence, decreases unemployment, boosts the economy, ​and creates safety standards 
for regulated products. Legalization of medicinal forms of marijuana looks different 
than commercial forms for recreational use — they have to abide by different baseline 
measures. 
 
Legalization does not mean immediate, certain success. A country cannot one day go 
from arresting people smoking on the sidewalk and seizing unapproved medicines to a 
harmonious society of free use. The principles of economics do not allow it. There must 
be some preparation in order to transition to that kind of society. However, some 
countries that have embraced legalization do not adequately prepare, and suffer the 
consequences.  European Cannabis watchdog group Prohibition Partners dubbed this 
the “Legal Lag” — without the construction of infrastructure and steady growth and 
processing of cannabis products to supply a newly robust industry, that newly legalized 
country would soon face an embarrassing shortage.  
“With legalisation nearly always implemented ahead of domestic cultivation schemes, 
European programmes are initially reliant on international supply from countries like 
the Netherlands and Canada until such time that they can draw from their own domestic 
cultivation. Anticipating patient numbers and creating a sustainable supply, both 
8 From “Evaluating alternative cannabis schemes,” by R. MacCoun and P. Reuter, 2001,​The British 
Journal of Psychiatry​, ​178​(2), 123-128. Cambridge University Press. doi:10.1192/bjp.178.2.123  
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internationally and domestically, have proven to be persistent stumbling blocks for 
burgeoning patient programmes and should serve as a lesson to those countries about to 




Decriminalization is characterized by three main modems. Removing criminal 
consequences for drug use and possession, sales in small mounts, and possession of 
drug paraphernalia, like syringes. The advantages of decriminalization are: freeing up 
money and resources to attend to more dire government duties, decrease prison 
population density, emphasizing cautious use of drugs over penal punishment, removal 




This is a precursor to decriminalization. In Europe, it is also referred to as 
“depenalisation.” In effect, this minimizes drug law transgressions from felonies to 
misdemeanors on an offender's record.  
 
Policy Models 
This is not a complete, comprehensive review of every existing policy model; there are 
too many to tackle in this paper. This presents the most common models: coffeeshops, 
social clubs, and licensing.   11
 
Coffeeshops are legal oases. These stores are allowed to sell small amounts of cannabis, 
as long as they abide by firm rules. Government supervisors check to see whether the 
stores are obeying the law at regular intervals. If there are any infractions, depending on 
the gravity of the situation, the store can face temporary closure or permanent 
shutdown. 
Cannabis Social Clubs operate much in the same way that co-operative grocery stores 
do. In order to purchase any products, one must register to be a member of the club, 
often at yearly intervals to discourage the membership of short-term tourists. One’s 
duties as a member include contributing to the cultivation of the plants. These clubs 
restrict usage to within the indoor area of the club, and the amount which a patron can 
consume per day.  The main difference between a social club and a coffee shop is the 
12
9 From “The European Cannabis Report - 5th Edition,” by Prohibition Partners, 2020. 
10 From “Drug Decriminalization” by Drug Policy Alliance, 2020, ​The Drug Policy Alliance. 
https://drugpolicy.org/issues/drug-decriminalization 
11 From “Cannabis policy, status and recent developments,” by European Monitoring Center for Drugs and 
Drug Addiction, 2020, www.emcdda.europa.eu/publications/topic-overviews/cannabis-policy/html_en. 
12 From “The Spanish Cannabis Social Club Model, Explained,” by C. Hudock, 2019, 
www.newfrontierdata.com/cannabis-insights/the-spanish-cannabis-social-club, New Frontier Data. 
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collective aspect. If a club starts to stray away from this, it makes competition more 
difficult for those clubs that do adhere to this structure. Because clubs are highly 
exclusive, many believe that they cannot be the only solution, or else the black market 
will continue to propagate.  
The treatment of marijuana and hemp for medical purposes is vastly different from 
recreational models. Use of cannabis as medicine depends on the laws and healthcare 
system of a given country. The typical system is predicated on licensing of 
pharmaceutical companies. Before a company is awarded a license, they must be 
thoroughly vetted and agree to a series of legal conditions; agreeing to use their crop 
strictly for healthcare. This system is flawed because large, already wealthy 





Due to the unexpected circumstances of removal from the originally intended place of 
study, the initial methods plan has to be shifted considerably. Interviews with local 
people and advocates in the European countries studied in this paper were attempted, 
but due to the chaotic situation at hand, requests for correspondence were ignored. In 
the process, this study unfortunately lost some nuance and depth. However, this paper 
still attempts to achieve a sophisticated analysis of policy through the review of primary 
and secondary sources within and without the subject nations. A variety of periodical 
articles, journal articles, biological context, demographic data and statistics, and 
anecdotal evidence comprise the sources of this paper. This paper does not use any set 
system of numerical analysis. The legalization of recreational marijuana is a larger focus 
of this paper than the medical system.  
 
A note about policy analysis: it is easy to conduct a rudimentary analysis of the impact of 
a policy by observing the situation before and after those particular regulations were 
passed in a government, and then inferring and attributing that any changes in statistics 
correlate with the policy implementation. It is more difficult to take a more holistic 
approach and assess all the factors surrounding the possible impacts of a policy — not 
just the before and after snapshot numbers. This paper will attempt to do the latter, 
however any failings in a sophisticated analysis can be attributed to lack of in-situ study 









Spain’s neighbor on the Iberian peninsula, Portugal, has seen immense drug policy 
reform over the last two decades. In 2001, they were the first country in the world to 
decriminalize possession and consumption of illicit substances. This radical step — after 
40 years of an iron dictatorship — triggered a culture shift in the traditionally 
conservative country.  
However, this sea change did not happen overnight. It took years for widespread social 
acceptance to take hold. Institutions like medical centers, housing agencies, mental 
health organizations, and educational organizations aided in altering the conversation 
surrounding drug use. The connotation of drug-related words in Portuguese shifted 
from “delinquent” to a more sympathetic “people who have drug addiction 
disorders/use drugs.”   
13
 
The Portugese case of decriminalization and cultural integration has been lauded by 
many drug reform advocates as a success story and the gold standard model. Assuming 
the “Domino Effect” is true in this case, Portugal was highly influential in the Spanish 
government’s decision to decriminalize. While it is true that statistics show that the 
policy has been successful in decreasing drug related fatalities, imprisonment, and 
disease, the policy did not eradicate all drug-related problems. Portuguese activists are 
still fighting for additional reforms and without a zealous government, the movement 
has stalled.  
 
Despite the Cato Institute’s celebration of Portugal’s drug reforms, the reforms were not 
a move toward liberty, but a shift from one arena of government involvement to another. 
Portugal’s Decriminalization Act is not based on a principle of an individual’s right to 
consume drugs free from state intrusion. The Act still prohibits drug use subject to 
citation, and cultivation for personal use remains criminally prohibited. Instead, 
Portugal’s Decree Law 30/2000 explicitly seeks to extend the protective function of the 
state by replacing criminal sanctions with the invitation to seek treatment.  
14
 
With a population of a little more than ten million, and borders that encapsulate only 
91,470 square kilometers, Portugal is one of the smaller countries in the European 
13 From “Portugal’s radical drugs policy is working. Why hasn’t the rest of the world copied it?” by S. 
Ferreira, 2017, ​The Guardian. 
www.theguardian.com/news/2017/dec/05/portugals-radical-drugs-policy-is-working-why-hasnt-the-world-c
opied-it 
14 From “Uses and Abuses of Drug Decriminalization in Portugal,” by H. Lacquer, 2014, ​Journal of the 
American Bar Association. 
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Union.  While they follow a parliamentary government system similar to other 
15
European countries, because of these demographic and other sociocultural differences, 
one cannot assume that copy and pasting the Portuguese model of drug 
decriminalization will result in the same radical results. However, policy experts can 
learn from the triumphs and hiccups of their implementation of these laws to improve 
upon them in other settings.  
 
Germany 
Germany is the most populous European country, with about 80 million citizens spread 
across a land area of 357,022 square kilometers.
,
 The legalization of marijuana strictly 
16 17
for medicinal use came about in March of 2017. To manage oversight, Germany then 
established its own domestic organization in charge of overseeing the licensing of new 
cannabis businesses and growers. The Cannabis Agency of BfArm recently approved 
growing licenses for three companies — Aphira, Aurora, and Demecan. These companies 
will complete their first harvest cycle this year and sell exclusively for German markets. 
This addition will decrease Germany’s reliance on other countries for stock and allow 
the country to cater to the approximately 50 thousand patients seeking these medicines.
 18
 
“The planned quantity in Germany will not be enough to avoid further supply 
bottlenecks. We expect three things: a fast start to cultivation, further licensing and, 
above all, falling prices for cannabis flowers in pharmacies.” said German Hemp 
Association CEO, Georg Wurth in an interview.  
19
 
Germany passes every country in the E.U. in being the largest and fastest-growing 
market for marijuana. In 2019, collective sales totaled to 170 million euros ($185.4 
million), accounting for nearly three quarters of retail cannabis sales in Europe.  One of 
20
15 From “Portugal” by CIA World Factbook, 2020, ​CIA World Factbook. 
https://www.cia.gov/library/publications/the-world-factbook/geos/po.html 
16 From “Germany” by CIA World Factbook, 2020, ​CIA World Factbook. 
https://www.cia.gov/library/publications/the-world-factbook/geos/po.html 
17 From “Living in the EU,” ​European Union​, 2020. 
www.europa.eu/european-union/about-eu/figures/living_en 
18 ​See 14. 
19 From “German Cannabis Cultivation Licenses Awarded to Aphira, Aurora, and Demecan,” by 
Prohibition Partners, 2019, 
www.prohibitionpartners.com/2019/04/05/germany-awards-domestic-cultivation-licences-to-aphria-aurora-
and-demecan. 
20 From “Medical Cannabis in Europe: The Markets and Opportunities,” by A. Pascual, 2020, ​Marijuana 
Business Daily International, ​mjbizdaily.com/intl. 
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the biggest business victories happened recently in 2019, when one of the most powerful 
cannabis companies in the world, Canopy Growth, acquired Germany’s preeminent 
pharmaceutical cannabinoid company, C3 for 226 million euros.   
21
 
All this rapid growth could come to a screeching halt. The future of cannabis’s place in 
Germany is riding on the next federal election in 2021. Even before coronavirus spread 
across the world, the split parties of the German national government were in a state of 
upheaval.  The progress of the last few years may meet an untimely fate if the next 
22
leader is unfavorable towards cannabis. 
 
Netherlands 
The Netherlands evokes images of a laid-back, happy-go-lucky populace, strolling on 
canal-lined streets, marijuana joints in-hand. While the stereotype is accurate — people 
smoking cannabis in public is highly common — there is more than meets the eye. The 
nation filigreed with canals is one of the wealthiest countries in the E.U., with one of the 
smallest land areas. It is home to 17 million people, who are known for their chill 
attitude towards social pastimes considered anathema in more conservative countries. 
For the average consumer, buying marijuana in a coffeeshop is as easy as buying a 
muffin. However, behind the ruse of open display cases, there are tons of rules 
controlling that purchase. One cannot buy more than five grams per person, the store 
cannot have more than 500 grams worth of inventory, the coffeeshops cannot advertise 
their products, one must be more than 18 years of age to purchase, and no coffeeshops 
can be located within 250 meters of a school. That last regulation is responsible for the 
recent demise of many coffeeshops, as residents file more complaints with the 
government. In the last 30 years, the number of coffeeshops in the country has fallen 
from 1,200 to 500.   
23
The few coffeeshops remaining have to keep up with high demand. For very popular 
establishments, 500 grams sells out quickly. So where does the stock come from? In 
many cases, black market wholesalers are the ones hustling more merchandise from 
nearby warehouses. Beyond the back door of the shop, the legality of the business 
becomes murky. Over time, businesses have become more furtive and tricky, and it is 
hard for the Office of Cannabis Management to enforce the law. This ‘grey market’ status 
quo is unsustainable. 
21 ​See 14. 
22 From “Why Angela Merkel’s successor resigned,” by J. Kirby, ​Vox Media​, 
www.vox.com/2020/2/10/21131546/angela-merkel-successor-resigned-germany-chancellor. 
23 From “As Dutch Coffeeshops Decrease, Illicit Demands Persist in the Netherlands,” by New Frontier 
Data, 2019, www.newfrontierdata.com/cannabis-insights/decline-in-dutch-cannabis-coffeeshops. 
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In the world of healthcare, about ten thousand patients are currently taking medical 
marijuana prescriptions in the Netherlands. The government legalized medical use in 
2003, and has since seen the popularity of such drugs to treat a diversity of ailments 
skyrocket. The company Bedrocan has monopolized the growth of the plant for use in 
medicines for years. A new law will hopefully open more space in the market for smaller 




The Spanish cannabis industry is still in its adolescence. Although progress in this 
industry has been slow, it does not mean it is not occuring. Recreational marijuana 
usage is most common among young people, with reports enumerating young men’s 
usage at 25 percent and that of young women at 11.5 percent. More than fifty million 
people call themselves Spaniards.   
25
 
The government hierarchy of drug management in Spain consists of the following. La 
delegación gubernamental por el Plan Nacional sobre Drogas (PNSD) is in charge of 
coordinating the national response to drug usage. This group renews their initiatives 
every few years based on changes in data over time. The delegation is supervised by the 
Minister of Health, Social Services and Equality. The Spanish Council for Drug 
Addiction and Other Addictions oversees the actions of the delegation and monitors the 
implementation of the policies. The Sectoral Conference on Drugs fosters cooperation 
24 ​See 14. 
25 From “Spain” by CIA World Factbook, 2020, ​CIA World Factbook. 
https://www.cia.gov/library/publications/the-world-factbook/geos/po.html 
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between the central government and 17 autonomous communities and two autonomous 
cities. The drug commissioners in each autonomous determine the appropriate drug 
plan for their region. Each commissioner works with the Government Delegation 
through the sector conference. It is through this food chain that drug policy in Spain 
operates.   
26
 
The consumption of drugs in public places and establishments is considered a grave 
offense, warranting a fine of up to 30,000 euros, according to the 2015 Law on the 
Protection of the Citizen’s Security law.  Companies must be authorized by the Spanish 
27
Agency for Medicines and Medical Products (AEMPS). The agency has approved eight 
licenses. Five went to raising crops for research purposes, two went to cultivation for 
medicinal purposes (one for education and training, one for production and 
manufacture), and one went to a company cultivating hemp for CBD products. Social 
clubs are the main system of recreational marijuana sale in Spain. If the country were to 
legalize, it would mean the certain death of these social clubs.  
 
There are not many instances of commentary on the drug situation in Spain from the 
royal family. One stands out: former King of Spain Juan Carlos I awarded the Order of 
Merit to the agencies handling drug control in 1996. The Gold Medal went to the head of 
the Ministry of Health, Consumption and Social Welfare, and Silver Medal and White 
Cross, to the head of the Government Delegation for the National Plan on Drugs. This 
type of public support is rare.  
28
 
Cuidadanos has voiced support for continuing to fund research for cannabis-based 
medicines. One of their party members, Congressman Francisco Egea, brought the issue 
to the parliament and helped advocate for research into this area. He was one of the 
reasons why the Congressional Health and Social Services Commission finally created a 
subcommittee to explore the possibilities of regulating cannabis for therapeutic use in 
April of 2016. However, progress was slow to start, and frustrated many patients seeking 
immediate relief from these unconventional sources. Today, there are many clinical 
studies currently being conducted in Spain to determine the effect of marijuana-based 
26 From “Spain: Country Drug Report 2019,” European Monitoring Center for Drugs and Drug Addiction, 
2019, 
www.emcdda.europa.eu/countries/drug-reports/2019/spain/national-drug-strategy-and-coordination_en 
27 Ley de protección de la seguridad ciudadana, Noticias Jurídicas ​§​ Section 2, Article 35. (2015). 
www.noticias.juridicas.com/base_datos/Penal/549725-lo-4-2015-de-30-mar-proteccion-de-la-seguridad-ci
udadana.html#c5s2 
28 Real Decreto, Disposiciones generales § Artículos 1 - 5. (1995).  
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Members of the progressive sects Podemos and PSOE (now working in coalition) are 
supporters of decriminalization. Party leader Pablo Iglesias has been an enthusiastic 
backer of legalization. It is stated as a policy promise on the Podemos website, “We will 
decriminalize the cultivation and possession of cannabis at a personal and collective 
level, we will regulate the activity of cannabis social clubs and we will establish the role 
of the State in guaranteeing the safety of consumers and in the control of production, 
distribution and consumption.”  The conservative party, Partido Popular, and the new 
30
ultra-right wing group Vox are both decidedly against legalization. In 2017, legalization 
was not a popular policy direction among Spaniards. Only 33.8 percent responded in a 
survey conducted by the P.N.S.D. that legalization would be an appropriate measure to 
solve the nation’s drug issues.   
31
 
Spain has the most land area of any European country, second only to France. Out of the 
505,370 square kilometers of land, 54 percent is designated for agriculture; sown with 
seeds of strawberries, grain, olives, and grapes. Agriculture related jobs employ about 
4.2 percent of the workforce. Southern Spain has been called the breadbasket of Europe. 
Currently, there are 2,000 square kilometers of land dedicated to growing cannabis.   32
 
Spain is still emerging from a long economic recession that lasted from 2008 to 2013. 
The GDP per capita is far from the highest in the European Union, and the country 
exports much of the goods and services produced domestically. Cannabis is a lucrative 
cash crop. The current industry in Spain largely gleans profits from exports of the plant 
to countries with more solidified systems like Germany and the Netherlands.  ​If Spain 33
grew, processed, and sold all cannabis products domestically, the nation would retain 
the profits and grow their own economy instead of losing that money to countries like 
Germany and the Netherlands. 
 
29 From “El Congreso pone a la cola la regulación del uso terapéutico del cannabis,” by A. Torices, 2017, 
La Verdad. ​www.laverdad.es/salud/congreso-pone-cola-20171203224046-ntrc.html 
30 From “Garantias Democraticas y la Ciudadania,” by Podemos, 2020, ​Podemos​. 
www.podemos.info/medida/despenalizar-el-cannabis-y-legalizar-su-uso-con-fines-medicinales/?lang=en 
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The main reasons why the regions of Spain have not yet moved to implement a more 
progressive policy model is that there has been a severe lack of unified momentum in el 
Congreso de los Diputados. Reform is either preceded by the pressure of the people, or 
the pressure of the market. In Spain’s case, it may be the market that finally persuades 
the parliament.  
 
Conclusion 
With its huge agricultural industry and need for economic stability, Spain has the 
potential to be a leader in Europe, if not the world, in cannabis cultivation. After 
comparing the current function of cannabis industries and their regulation in various 
European countries to reach a conclusion about the most successful policy and business 
model for cannabis in Spain. Based on the cases observed in Germany, Portugal, and 
The Netherlands, the best model for Spain to strive for appears to be a combination. 
Spain should learn from the domestic vertical integration of Germany, the cultural shift 
in Portugal, and the tolerance and market diversification of the Netherlands. Combining 
these ingredients, the nation known for its pork can become famous for its cannabis 
market. 
The Domino Effect has proven to be true. For countries hesitant on some form of 
legalization now, it is inevitable that they will embrace at least partial legalization over 
the next few decades. Now, especially in the aftermath of a pandemic, legalization in 
Spain is on the horizon.  The policy decisions made today will determine the success of 
34
cannabis in Spain tomorrow. 
What was once considered mere fodder for the fringe, counter-culture is now flooding 
the mainstream market. The novel nature of this industry means innovation is occurring 
at all stages: genetic breeding, cultivation, processing and extraction, marketing, 
education, pharmaceutical development, and more. What is exciting about this area is 
that there is still so much we don't know. Researchers and policy makers can trial and 
error every system, but we still cannot know for certain every consequence of an 
alteration in cannabis policy. Harnessing that uncertainty and turning it into a learning 
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